主页
市场
图表与思路
Algo
新闻
Store
经纪商
下载
经济日历
交易信号
网页端
键入
/
进行搜索:@user,$symbol
查找
登录
创建账户
中文
English
Русский
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
KURA
#2246
Kura Oncology, Inc.
8.7
3
+4.30%
版块:
基础:
利润货币:
日范围
年范围
日变化
+4.30%
每月变动
+3.44%
6个月变化
+9.54%
年变化
+14.87%
前一天收盘价
8.3
7
Open
8.7
3
Bid
Ask
Low
8.7
3
High
8.7
3
交易量
85
市场
股票
医疗保健
KURA
Open full chart
Financials
Overview
声明
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
66.21 M
66.61 M
68.44 M
76.14 M
80.75 M
—
Valuation ratios
Enterprise value
1.84 B
841.93 M
772.88 M
1.13 B
478.91 M
2.09 B
Price to earnings ratio
—
—
-5.94
-7.38
-4.31
-13.62
Price to sales ratio
—
—
—
—
13.93
—
Price to cash flow ratio
—
—
-7.33
-9.01
5.59
23.04
Price to book ratio
—
—
1.92
2.83
1.81
3.07
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.14
0.24
0.3
0.34
0.23
0.31
Return on equity %
0.15
0.26
0.32
0.38
0.42
0.73
Return on invested capital %
-4 731.27
-4 247.5
-4 669.95
-4 398.28
2 520.1
2 898.67
Gross margin %
—
100
—
—
100
—
Operating margin %
—
-61.81 K
—
—
358.55
—
EBITDA margin %
—
—
—
—
—
—
Net margin %
—
61.54 K
—
—
322.89
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
24.49
23.26
18.56
12.26
9.46
28.81
Inventory turnover
—
—
—
—
—
—
Asset turnover
—
0
—
—
0.09
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
0.01
0.01
0.02
0.02
0.01
0.04
Long term debt to total equity ratio
0.01
0.01
0.02
0.02
0.02
0.08
Per share metrics
Operating cash flow per share
—
—
1.64
1.7
1.56
2.07
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
—
—
6.54
5.79
8.44
29.44
Net current asset value per share
—
—
6.66
5.91
8.64
31.55
Tangible book value per share
—
—
6.27
5.43
4.8
15.22
Working capital per share
—
—
6.3
5.42
7.73
27
Book value per share
—
—
6.27
5.43
4.8
15.22
新闻
Earnings Preview: Entrada Therapeutics, Inc. (TRDA) Q4 Earnings Expected to Decline
Earnings Preview: Kura Oncology (KURA) Q4 Earnings Expected to Decline
Citizens重申Kura Oncology股票市场表现优于大盘评级
Citizens reiterates Market Outperform rating on Kura Oncology stock
Kura Oncology’s chief legal officer sells $94,827 in stock
Kura Oncology首席商务官Powl出售价值54,266美元的股票
Kura Oncology CCO Powl sells $54,266 in stock
Kura Oncology首席医疗官Leoni出售价值6.9万美元股票
Kura Oncology SVP sells $60k in shares
Kura Oncology COO Ford sells $15,339 in stock
Kura Oncology’s chief medical officer, Leoni, sells $69k in stock
Kura oncology CSO Burrows sells $11k in shares